Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 8/20 | 1.00 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.80 |
| ▸ | MAOB | P27338 | 1/20 | 0.77 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.74 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.72 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.71 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207018 | 1.00 | NR4A2 (1.00) | NR4A2SRD5A2MAOBMRGPRX4MEN1 | |
| Hydrochloric Acid SCHEMBL4748074 | 0.98 | NR4A2 (0.97) | NR4A2SRD5A2MAOBMRGPRX4MEN1 | |
| SCHEMBL1122713 | 0.97 | NR4A2 (0.94) | NR4A2SRD5A2MAOBMRGPRX4MEN1 | |
| SCHEMBL1123155 | 0.95 | NR4A2 (0.91) | NR4A2SRD5A2MAOBMRGPRX4MEN1 | |
| SCHEMBL4406160 | 0.93 | NR4A2 (0.87) | NR4A2SRD5A2MRGPRX4SMN1; SMN2 | |
| SCHEMBL30994900 | 0.90 | NR4A2 (0.82) | NR4A2SRD5A2MAOBMRGPRX4MEN1 | |
| SCHEMBL27815839 | 0.90 | NR4A2 (0.82) | NR4A2SRD5A2MAOBMRGPRX4MEN1 | |
| SCHEMBL4138759 | 0.90 | NR4A2 (0.81) | NR4A2MRGPRX4SMN1; SMN2 | |
| SCHEMBL7908051 | 0.90 | SRD5A2 (0.85) | NR4A2SRD5A2MAOBMRGPRX4MEN1 | |
| SCHEMBL3442746 | 0.88 | NR4A2 (0.79) | NR4A2SRD5A2MAOBMRGPRX4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017132775-A1 | NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEIOMYOMA | VITEAVA PHARMACEUTICALS INC. (CA) | 2017-08-10 | — | — | WO | claimed |
| CN-1732161-A | 1,3-diamino-2-hydroxypropane pro-drug derivatives | ELAN PHARM INC (US) | 2006-02-08 | — | — | CN | claimed |
| CN-1132508-A | Piperazine derivatives | REORDATI IND CHIMICA E FARMACE (CH) | 1996-10-02 | — | — | CN | claimed |
| JP-63091347-A | — | — | None | — | — | JP | disclosed |
| US-12600703-B2 | Methods of synthesizing farnesyl dibenzodiazepinones | AMO PHARMA LTD. (GB) | 2026-04-14 | — | — | US | disclosed |
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-20 | — | — | US | disclosed |
| US-20250214974-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-12286421-B2 | Inhibiting monoacylglycerol lipase (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250084065-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-0135838-B1 | 3-PHENYL-4-METHOXYCARBONYL PYRAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AGAINST PLANT GROWTH | BASF Aktiengesellschaft (DE) | 1990-04-18 | — | — | EP | disclosed |
| JP-S6391347-A | PRODUCTION OF HYDROXYANTHRAQUINONE DERIVATIVE | MITSUBISHI KASEI CORP | 1988-04-22 | — | — | JP | disclosed |
| US-4537617-A | HEBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1985-08-27 | — | — | US | disclosed |
| EP-0135838-A2 | 3-Phenyl-4-methoxycarbonyl pyrazoles, process for their preparation and their use against plant growth | BASF Aktiengesellschaft (DE) | 1985-04-03 | — | — | EP | disclosed |
| US-4386031-A | ANTICOAGULANTS; ANTIALLERGENS; ANTINFLAM-MATORY AND ANTILIPEMIC AGENTS; ANTIHISTAMINES; CARDIOVASCULAR DISORDERS | A. NATTERMANN & CIE GMBH (DE) | 1983-05-31 | — | — | US | disclosed |
| US-4235913-A | ANALGESICS, TRANQUILIZERS | PFIZER INC. (US) | 1980-11-25 | — | — | US | disclosed |
| US-4165323-A | ANALGESICS, TRANQUILIZERS | PFIZER INC. (US) | 1979-08-21 | — | — | US | disclosed |
| US-4118559-A | CNS AGENTS, ANALGESICS, TRANQUILIZERS | PFIZER INC. (US) | 1978-10-03 | — | — | US | disclosed |
| US-3953595-A | Substituted benzoic acid hypolipemic agents | PFIZER INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214974-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LIPC | NR4A2 4573/4885SRD5A2 3568/4885MAOB 491/4885 |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | NR4A2 267/4885SRD5A2 733/4885MAOB 3077/4885 |
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | NR4A2 2421/4885SRD5A2 1759/4885MAOB 2014/4885 |
| US-20250084065-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LPL | NR4A2 2851/4885SRD5A2 1843/4885MAOB 620/4885 |
| US-12286421-B2 | Inhibiting monoacylglycerol lipase (MAGL) | MGLL, PNLIP, LIPC | NR4A2 4573/4885SRD5A2 3568/4885MAOB 491/4885 |
| US-12600703-B2 | Methods of synthesizing farnesyl dibenzodiazepinones | NR1H2, NR1H3, NR1H4 | NR4A2 715/4885SRD5A2 170/4885MAOB 2969/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | NR4A2 1989/4885SRD5A2 1430/4885MAOB 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.